Incyte (INCY) Stock Price, Quote, News & History

SPY767.53−1.35%QQQ728.11−2.08%BTC/USD81,521.45−1.90%DIA513.47−0.53%GLD374.24−1.95%TLT78.73+0.46%

Premium

Incyte Corp (INCY) Stock Price, Quote, News & History

INCYNASDAQ

Trade with Public

$112.00

3.383.12%

Last update: Oct 14, 2:05 PM

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

$108.61

Volume / Avg.

839.04K / 1.62M

Day Range

$112.01 - $112.03

52 Wk Range

82.82 - 132.60

Market Cap

$22.57B

P/E Ratio

13.84

Dividend Yield

Exchange

NASDAQ

RSI

Short Interest

8.4%

Days to Cover

6.06

Recent Incyte Corp News

FDA Expands Approval Of Eli Lilly's Olumiant For Adolescents with Autoimmune Hair Loss

FDA approves Eli Lilly's once-daily pill Olumiant for adolescents aged 12 and older with severe alopecia areata following Phase 3 trials.

Vandana Singh

Mirum Pharmaceuticals and Incyte Compete Regeneron with Abnormal Bone Formation Treatment

The FDA approved Atebrioz by Mirum Pharmaceuticals and Incyte to treat FOP in patients aged 12 and older, reducing abnormal bone formation.

Vandana Singh

Ericsson, Lexeo Therapeutics And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session

U.S. stock futures were mixed. Ericsson fell 4.3% after a Morgan Stanley downgrade; Quest Diagnostics, Rambus and others also declined premarket.

Avi Kapoor

Charles Schwab, UnitedHealth And Cleveland-Cliffs: CNBC’s ‘Final Trades’

CNBC final trades: Pros picked Schwab, Cleveland-Cliffs, UnitedHealth and Incyte; shares posted mixed moves Wednesday.

Avi Kapoor

This Small Biotech’s Cancer Drug Could Reach $1.3 Billion In Peak Sales

William Blair initiates Zentalis (ZNTL) at Outperform, citing a $1.3B peak sales potential for lead cancer drug azenosertib.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

1.98B

Investing Cash Flow (TTM)

-224.83M

Financing Cash Flow (TTM)

275.24M

Free Cash Flow (TTM)

1.89B

Capital Expenditure (TTM)

-89.24M

Net Change in Cash (TTM)

2.03B

Analyst Trends and Forecast

Jun

Jul

Aug

Sep

Oct

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

2.7

Hold

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$17.52B

PE Ratio (TTM)

13.84

PE Ratio (FWD)

12.59

PEG Ratio (TTM)

PS Ratio (TTM)

3.83

PB Ratio (TTM)

3.47

Earnings Yield % (TTM)

7.23%

Earnings Yield % (FWD)

7.94%

EV / EBITDA (TTM)

8.47

Price / EBITDA (TTM)

10.78

Price / Free Cash Flow (TTM)

11.79

Book Value / Share

$31.30

Company Debt

Total Debt

LT Debt

LT Debt Issuance (TTM)

LT Debt Repayment (TTM)

-$4.64M

Total Cash

$3.98B

Debt to Equity

0.01

Issuance of Debt (TTM)

-$4.64M

Repayment of Debt (TTM)

-$4.64M

Key Statistics

Open

$108.61

Volume / Avg.

839.04K / 1.62M

Day Range

$112.01 - $112.03

52 Wk Range

82.82 - 132.60

Market Cap

$22.57B

P/E Ratio

13.84

Dividend Yield

Exchange

NASDAQ

RSI

Short Interest

8.4%

Days to Cover

6.06

About Incyte Corp

Sector

Health Care

Industry

Biotechnology

Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include...

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

FAQ

How do I buy Incyte (INCY) stock?

You can purchase shares of Incyte (NASDAQ:INCY) through any online brokerage.

View our list of the best stock brokerages

Who are Incyte (INCY) competitors?

Other companies in Incyte’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Moderna Inc (NASDAQ:MRNA).

What is the forecast, or price target, for Incyte (INCY) stock?

Incyte has a consensus price target of $116.71.

What is the current price for Incyte (INCY)?

The stock price for Incyte (NASDAQ: INCY) is $112.005 last updated October 14, 2026 at 2:05 PM EDT.

Does Incyte (INCY) pay a dividend?

There are no upcoming dividends for Incyte.

When is Incyte (NASDAQ:INCY) reporting earnings?

Incyte does not have any upcoming earnings scheduled.

Is Incyte (INCY) going to split?

There is no upcoming split for Incyte.

What sector and industry does Incyte (INCY) operate in?

Incyte is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Incyte Corp (INCY) Stock Price, Quote, News & History

Incyte (INCY) Stock Price, Quote, News & History | Benzinga

Key Statistics

Recent Incyte Corp News

FDA Expands Approval Of Eli Lilly's Olumiant For Adolescents with Autoimmune Hair Loss

Mirum Pharmaceuticals and Incyte Compete Regeneron with Abnormal Bone Formation Treatment

Ericsson, Lexeo Therapeutics And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session

Charles Schwab, UnitedHealth And Cleveland-Cliffs: CNBC’s ‘Final Trades’

This Small Biotech’s Cancer Drug Could Reach $1.3 Billion In Peak Sales

Financials

Cash Flows

Analyst Trends and Forecast

Analyst Rating and Forecast

Valuation Metrics

Company Debt

Key Statistics

About Incyte Corp

Edge Rankings

Stock Score Locked: Want to See it?

FAQ

How do I buy Incyte (INCY) stock?

Who are Incyte (INCY) competitors?

What is the forecast, or price target, for Incyte (INCY) stock?

What is the current price for Incyte (INCY)?

Does Incyte (INCY) pay a dividend?

When is Incyte (NASDAQ:INCY) reporting earnings?

Is Incyte (INCY) going to split?

What sector and industry does Incyte (INCY) operate in?

Key Statistics

Recent Incyte Corp News

FDA Expands Approval Of Eli Lilly's Olumiant For Adolescents with Autoimmune Hair Loss

Mirum Pharmaceuticals and Incyte Compete Regeneron with Abnormal Bone Formation Treatment

Ericsson, Lexeo Therapeutics And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session

Charles Schwab, UnitedHealth And Cleveland-Cliffs: CNBC’s ‘Final Trades’

This Small Biotech’s Cancer Drug Could Reach $1.3 Billion In Peak Sales

Financials

Cash Flows

Analyst Trends and Forecast

Analyst Rating and Forecast

Valuation Metrics

Company Debt

Key Statistics

About Incyte Corp

Edge Rankings

Stock Score Locked: Want to See it?

Bulls vs Bears

FAQ

How do I buy Incyte (INCY) stock?

Who are Incyte (INCY) competitors?

What is the forecast, or price target, for Incyte (INCY) stock?

What is the current price for Incyte (INCY)?

Does Incyte (INCY) pay a dividend?

When is Incyte (NASDAQ:INCY) reporting earnings?

Is Incyte (INCY) going to split?

What sector and industry does Incyte (INCY) operate in?

Bulls vs Bears